Eli Lilly developed tirzepatide, marketed as Mounjaro for type 2 diabetes.
Tirzepatide is a medicine that activates receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. This dual action helps improve blood-sugar control and can reduce appetite and body weight. Eli Lilly markets the drug under the name Mounjaro for type 2 diabetes.
The United States Food and Drug Administration approved Mounjaro in 2022. Tirzepatide is also marketed as Zepbound in the United States for chronic weight management in eligible adults. These are different brand names for the same active ingredient, used under separate regulatory indications.
Eli Lilly was founded in Indianapolis in 1876 by Colonel Eli Lilly, a pharmaceutical chemist. The company is often confused with the manufacturers of semaglutide products, which include Novo Nordisk. Tirzepatide and semaglutide are different medicines, although both act on pathways associated with appetite and glucose regulation.